Allergan result proves Valeant is a shrewd negotiator, says Paradigm


In refusing to overpay for Allergan, Valeant Pharmaceuticals (TSX:VRX) exhibited exactly the kind of discipline that investors should admire in the company, says Paradigm Capital analyst Alan Ridgeway. Yesterday, a saga that began in April ended for Valeant when Dublin-based Actavis Plc’s offer of $219 a share in cash and stock was accepted by the […]

Prometic Life Sciences gets price target raise at Paradigm

Prometic Life Sciences CEO Pierre Laurin.

Investors should focus on Prometic Life Science’s (TSX:PLI) deep product development pipeline instead of its predictably lumpy revenue, says Paradigm Capital analyst Alan Ridgeway. Last Thursday, Prometic reported its Q3, 2014 results. The company lost $20.7-million on revenue of $2.3-million. Management noted that its year to date product sales of $7.3-million is still ahead of […]

Nuvo Research rises after regaining Pennsaid 2% marketing rights

pennsaid cropped

Shares of Nuvo Research (TSX:NRI) are up today after the company announced it had reacquired the rights to market osteoarthritis knee pain treatment Pennsaid 2% in Israel, South Africa, South America and Central America. The company says it will now seek partners to market the treatment in all areas except for Russia, Greece and Canada, […]

Tribute Pharmaceuticals CEO Rob Harris talks to Cantech Letter

Tribute Pharmaceuticals CEO Rob Harris.

Ask an investor to talk about life sciences stocks and it won’t be long before the word “risk” comes up. The popular conception of biotech is that every company is a swing-for-the-fences slugger burning through cash in a furious attempt at scoring the next home run drug. But modern business models are emerging that allow […]

Prometic Plans to Move Quickly With Rare Disease Candidate

Prometic Life Sciences CEO Pierre Laurin.

This morning, Prometic Life Sciences (TSX:PLI) announced that the FDA has cleared the company’s IV plasminogen to enter human testing for the treatment of hypoplasminogenemia. With its Investigational New Drug (IND) application approved, Prometic isn’t wasting anytime, it plans to commence a 6 patient Phase I study this quarter. That study will lead into a […]

Cipher Pharmaceuticals has multiple ways to create shareholder value, says Donville

"My guess is we are going to get reconciliation on this, one way or the other, in the next six months," says Jason Donville of Cipher Pharmaceuticals. "They're either going to buy a bunch of stuff and get a big pop in their rating, or they're going to get taken out by somebody".

Investors looking at Cipher Pharmaceuticals (TSX:DND) should know there is more than one way the company could deliver value for shareholders, says one portfolio manager. Jason Donville, President & CEO of Donville Kent Asset Management was on BNN’s “Market Call” Friday and revealed his current top picks. The portfolio manager says Cipher Pharma is valuable […]

TSO3 Awaits FDA Verdict After Label Submission

This morning, Quebec City based TSO3 (TSX: TOS) updated the markets on the status of their FDA 510(k) filing for their low temperature hospital sterilizer, Sterizone VP4. In a press release, the company stated that it has submitted revised labeling to FDA for both the sterilizer and accessory devices. In August of this year, the […]

Tekmira rises as production of Ebola treatment begins


Shares of Burnaby-based Tekmira (TSX:TKM, NASDAQ:TKMR) are up today after the company late yesterday announced it has started limited GMP manufacture of a new therapeutic that specifically targets the Ebola-Guinea variant, the viral variant responsible for the Ebola epidemic in West Africa. The company says the product should be available by December. In August, the […]

Valeant Q3 could prove it doesn’t need Allergan, says Paradigm


A strong third quarter from Valeant Pharmaceuticals (TSX:VRX) on October 20th could prove to the street that the company’s legacy business is strong and sustainable, says Paradigm Capital analyst Alan Ridgeway. In a research update to clients this morning, Ridgeway maintained his “Buy” rating and $160.00 target on Valeant, implying a return of 39% at […]